# OnCo record cynk-001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cynk-001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cynk-001" ;
  schema:name "CYNK-001"@en ;
  schema:alternateName "placental-derived natural killer (CYNK) cells"@en ;
  schema:description "CYNK-001 is an experimental allogeneic, cryopreserved, off-the-shelf natural killer cell therapy derived from placental haematopoietic stem cells from Celularity, in phase 1 trials for acute myeloid leukaemia, glioblastoma and multiple myeloma; its current status is not stated."@en ;
  schema:url <https://onco.cc/drugs/cynk-001/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://celularity.com/nk-cell-platform/>, <https://celularity.com/nk-cell-platform/>, <https://clinicaltrials.gov/api/v2/studies/NCT04310592>, <https://clinicaltrials.gov/api/v2/studies/NCT04489420>, <https://clinicaltrials.gov/search?intr=CYNK-001> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic, cryopreserved, off-the-shelf natural killer (NK) cell therapy derived from placental haematopoietic stem cells" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:companies <https://onco.cc/companies/celularity/> ;
  onco:trials <https://onco.cc/trials/nct04310592/>, <https://onco.cc/trials/nct04489420/>, <https://onco.cc/trials/nct04309084/>, <https://onco.cc/trials/nct05218408/> .